drugset / Trial / NCT01859988

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT01859988

Phase 2 Completed 380 enrolled Regeneron Pharmaceuticals Sanofi · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).

Timeline

Start
2013-05
Primary completion
2014-05
Completion
2014-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody 100 mg Subcutaneous
Subject Dupilumab Monoclonal antibody 200 mg Subcutaneous
Subject Dupilumab Monoclonal antibody 300 mg Subcutaneous

Indications